While the prevalence of therapy-related myeloid neoplasms was higher in patients with ovarian cancer that harbored a deleterious mutation in BRCA1, BRCA2, RAD51C, or RAD51D—four genes that are commonly mutated in ovarian cancer—at 15 of 369 (4.1%) for those with mutation-containing cancers compared to 7 of 683 (1.0%) for those without mutations, the incidence was indistinguishable in patients with germline vs. somatic mutations in these genes. Here, RAD51D is linked to ovarian cancer.